- $183.77m
- $58.47m
- $72.76m
Compugen rises on $6 mln milestone payment from AstraZeneca
Brief: Compugen Ltd Announces Milestone Payment From Astrazeneca Triggered By First Patient Dosed With Tigit Bispecific Derived From COM902
Brief: Compugen To Present Clinical Data From Anti-TIGIT COM902 Monotherapy And Triple Combination Dose Escalation Studies At SITC 2021
Brief: Compugen Announces Lung Cancer Treatment To Enter Phase 1/2 Study
Brief: Compugen Q2 Loss Per Share $0.11
Brief: Compugen Doses First Patient In Phase 1/2 Triple Combination Cohort Expansion Of COM701
Brief: Compugen Doses First Patient In Phase 1 Combination Study Of Com902 And Com701 In Patients With Advanced Malignancies
Brief: Compugen Doses First Patient In Com701/Opdivo® Phase 1B Cohort Expansion Study
Brief: Compugen Announces Updated Data From Phase 1 Study Of Com701
Brief: Compugen Reports Q1 Loss Per Share Of $0.12
Brief: Compugen Announces Expansion Of Research Collaboration With Johns Hopkins University
Brief: Compugen Publishes Review On Biology And Potential Therapeutic Relevance Of Dnam-1 Axis In Cancer Immunotherapy
U.S. RESEARCH ROUNDUP-Agios Pharmaceuticals, Life Storage, Pactiv Evergreen
Brief: Compugen Announces Data Update From COM701 Phase 1 Clinical Trial
Brief: Compugen Reports Fourth Quarter And Full Year 2020 Results
Record redemption in Ark ETF sparks liquidity worries
Record redemption in Ark ETF sparks liquidity worries
Brief: Compugen Expands Clinical Collaboration Agreement With Bristol Myers Squibb With Phase 1B Combination Study Of Com701 With Opdivo®
Brief: Compugen Announces First Development Milestone In License Agreement With Astrazeneca For The Development Of Bispecific And Multi-Specific Antibody Products